Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

NCT02091531 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: MLN0128

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]